• Caris Molecular Intelligence Service examines the genetic and molecular makeup that is unique to each patient’s tumour. By comparing the tumour's information with data from clinical studies from thousands of the world's leading cancer researchers, Caris can help the physician determine which treatments are likely to be most effective and which treatments are likely to be ineffective for each patient. Caris Molecular Intelligence can be used to inform treatment selection when treating aggressive or rare tumors, or refractory disease. 


  • The Prosigna Breast Cancer Prognostic Gene Signature Assay is indicated in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with standard of care, either as:

    • A prognostic indicator for distant recurrence-free survival at 10 years in post-menopausal women with Hormone Receptor- Positive (HR+), lymph node-negative, Stage I or II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors.
    • A prognostic indicator for distant recurrence-free survival at 10 years in post-menopausal women with Hormone Receptor-Positive (HR+), lymph node-positive (1–3 positive nodes), Stage II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors. The device is not intended for patients with 4 or more positive nodes. 

  • InVisionSeq is a qualitative laboratory developed test that uses targeted advanced sequencing technology to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions and deletions (InDels) in selected genes from DNA isolated from plasma samples from patients.


                                                                                                    More about Invision Seq

  • InVisionFirst-Lung is a qualitative laboratory developed test that uses targeted advanced sequencing technology to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions and deletions (InDels) and structural variants in selected genes from DNA isolated from plasma samples from patients with non-small cell lung cancer (NSCLC). The test is intended to aid clinicians in treatment decisions for NSCLC patients



                                                                                                       More about Invision First-lung

  • SelectMDx helps identify patients at increased risk for aggressive disease, thereby aiding in the selection of men for prostate biopsy. 
    SelectMDx provides the likelihood of detecting prostate cancer upon biopsy, and the probability for high-grade versus low-grade disease, with an area under the curve (AUC) of 0.89 (95% CI: 0.86-0.92).

    High Risk men may benefit from prostate biopsy and early detection.
    Low Risk men may avoid unnecessary invasive procedures with routine follow up and screening.



  • HerediGENE is a test that fully analyzes a panel of genes, including BRCA1 and BRCA2, which are associated with increased risk of developing breast, ovarian and other hereditary cancers.
    HerediGENE provides valuable information that can be utilized for reducing the risk of cancer development by assisting the treating physicians to individualize surgical and pharmaceutical management.  In addition, it can be used to identify those family members at risk of developing cancer who can benefit from risk reduction management. Furthermore, those family members that do not carry the pathogenic mutation identified in the family can be relieved of the stress of developing hereditary cancer and forego unnecessary interventions.

                                                                                                                         More about HerediGene

  • Immunoscore® is an in vitro diagnostic test predicting the risk of relapse in early stage colon cancer patients, by measuring the host immune response at the tumor site.

    It is a risk-assessment tool that provides independent and superior prognostic value than the usual tumor risk parameters, and should be used as an adjunct to the TNM classification (Pagès F et al. The Lancet 2018, Sinicrope F et al. J Clin Oncol 2018). Immunoscore® can thus improve individual patient treatment strategies, particularly the modulation of adjuvant chemotherapy in stage II and stage III.

     

                                                                                                                      More about Immunoscore